Adapted problem adaptation therapy for depression in mild to moderate Alzheimer's disease dementia: A randomized controlled trial.
Alzheimer's disease
clinical trial
depression
mood
problem adaptation therapy
psychological
psychotherapy
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
13 Mar 2024
13 Mar 2024
Historique:
revised:
26
01
2024
received:
16
10
2023
accepted:
02
02
2024
medline:
13
3
2024
pubmed:
13
3
2024
entrez:
13
3
2024
Statut:
aheadofprint
Résumé
Trials of effectiveness of treatment options for depression in dementia are an important priority. Randomized controlled trial to assess adapted Problem Adaptation Therapy (PATH) for depression in mild/moderate dementia caused by Alzheimer's disease. Three hundred thirty-six participants with mild or moderate dementia, >7 on Cornell Scale for Depression in Dementia (CSDD), randomized to adapted PATH or treatment as usual. Mean age 77.0 years, 39.0% males, mean Mini-Mental State Examination 21.6, mean CSDD 12.9. For primary outcome (CSDD at 6 months), no statistically significant benefit with adapted PATH on the CSDD (6 months: -0.58; 95% CI -1.71 to 0.54). The CSDD at 3 months showed a small benefit with adapted PATH (-1.38; 95% CI -2.54 to -0.21) as did the EQ-5D (-4.97; 95% CI -9.46 to -0.48). An eight-session course of adapted PATH plus two booster sessions administered within NHS dementia services was not effective treatment for depression in people with mild and moderate dementia. Future studies should examine the effect of more intensive and longer-term therapy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Institute for Health Research Health Technology Assessment Programme
ID : 16/155/01
Informations de copyright
© 2024 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Asmer MS, Kirkham J, Newton H, et al. Meta-analysis of the prevalence of major depressive disorder among adults with dementia. J Clin Psychiatry. 2018;79:17r11772.
Peters ME, Schwartz S, Han D, et al. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: the cache county dementia progression study. Am J Psychiatry. 2015;172:460-465.
Kraup BA, Loreck D, Gruber-Baldini AL, et al. Depression and its relationship to function and medical status by dementia status in nursing home admissions. Am J Geriatr Psychiatry. 2007;15:438-442.
Baharudin AD, Din NC, Subramaniam P, Razali R. The associations between behavioural-psychological symptoms of dementia and coping strategy; burden of care and personality style among low-income caregivers of patients with dementia. BMC Public Health. 2019;19(4):447.
Dudas R, Malouf R, McCleery J, Dening T. Antidepressants for treating depression in dementia. Cochrane Database Syst Rev. 2018;8:1465-1858.
Banerjee S, Hellier J, Dewey M, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet. 2011;378:403-411.
Orgeta V, Leung P, Del-Pino-Casado R, et al. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment. Cochrane Database Syst Rev. 2022;4:CD009125.
Watt JA, Goodarzi Z, Veroniki AA, et al. Comparative efficacy of interventions for reducing symptoms of depression in people with dementia: systematic review and network meta-analysis. BMJ. 2021;372:532.
Folstein MF, Folstein SE, McHugh PR. Mini-mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
Kiosses DN, Ravdin LD, Gross JJ, Raue P, Kotbi N, Alexopoulos GS. Problem adaptation for older adults with major depression and cognitive impairment: a randomised clinical trial. JAMA Psychiatry. 2015;72:22-30.
McCombie C, Cort E, Gould RL, et al. Adapting and optimizing problem adaptation therapy (PATH) for people with mild-moderate dementia and depression. Am J Geriatr Psychiatry. 2021;29:192-203.
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dis. 2011;7:263-269.
Molloy DW, Alemayehu E, Roberts R. Reliability of a standardized mini-mental state examination compared with the traditional mini-mental state examination. Am J Psychiatry. 1991;148:102-105.
Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell scale for depression in dementia. Biol Psychiatry. 1988;23:271-284.
Smith LC, Lamping DL, Banerjee S, et al. Development of a new measure of health-related quality of life for people with dementia: DEMQOL. Psychol Med. 2007;37:737-747.
EuroQoLGroup. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-208.
Bucks RS, Ashworth DI, Wilcock GK, et al. Assessment of activities of daily living in dementia: development of the Bristol activities of daily living scale. Age Ageing. 1996;25:113-120.
Shankar K, Walker M, Frost D, Orrell M. The development of a valid and reliable scale for rating anxiety in dementia (RAID). Aging Ment Health. 1999;16:592-602.
Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist. 1980;20:649-655.
Goldberg D, Williams P. A User's Guide to the General Health Questionnaire. NFER-Nelson; 1988.
Beecham JK, Knapp MR. Costing psychiatric interventions. In: Thornicroft G, Brewin C, Wing JK, eds. Measuring Mental Health Needs. Gaskell; 1992.
Phung KTT, Waldorff FB, Buss DV, et al. A three-year follow-up on the efficacy of psychosocial interventions for patients with mild dementia and their caregivers: the multicentre, rater-blinded, randomised Danish Alzheimer Intervention Study (DAISY). BMJ Open. 2013;3:e003584. doi:10.1136/bmjopen-2013-003584
Woods R, Bruce E, Edwards R, Elvish R, Hoare Z. REMCARE: reminiscence groups for people with dementia and their family caregivers-effectiveness and economic analysis 2016. PLoS One. 2016;11(4):e0152843. doi:10.1371/journal.pone.0152843
Costello H, Roiser JP, Howard R. Antidepressant medications in dementia: evidence and potential mechanisms of treatment-resistance. Psychol Med. 2023;53:654-667.
DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. Stat Med. 1994;13(13-14):1341-1352. doi:10.1002/sim.4780131308. discussion 1353-6.
Freemantle N. Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic? BMJ. 2001;322(7292):989-991. doi:10.1136/bmj.322.7292.989
Cuijpers P, Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds CF. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry. 2014;13:56-67.
Cuijpers P, Noma H, Karyotaki E, Vinkers CH, Cipriani A, Furukawa TA. A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry. 2020;19:92-107.
Wong R, Amano T, Lin S-Y, Zhou Y, Morrow-Howell N. Strategies for the recruitment and retention of racial/ethnic minorities in Alzheimer disease and dementia clinical research. Curr Alzheimer Res. 2019;16:458-471.
National Institute for Health and Social Care Excellence. Depression in adults: treatment and management. 2022. https://www.nice.org.uk/guidance/ng222